Division of Molecular Genetics, German Cancer Research Center, Heidelberg, 69120, Germany.
Department of Internal Medicine III, Ulm University Hospital Ulm, 89081, Germany.
Haematologica. 2022 Mar 1;107(3):604-614. doi: 10.3324/haematol.2020.265777.
Clonal evolution is involved in the progression of chronic lymphocytic leukemia (CLL). In order to link evolutionary patterns to different disease courses, we performed a long-term longitudinal mutation profiling study of CLL patients. Tracking somatic mutations and their changes in allele frequency over time and assessing the underlying cancer cell fraction revealed highly distinct evolutionary patterns. Surprisingly, in long-term stable disease and in relapse after long-lasting clinical response to treatment, clonal shifts are minor. In contrast, in refractory disease major clonal shifts occur although there is little impact on leukemia cell counts. As this striking pattern in refractory cases is not linked to a strong contribution of known CLL driver genes, the evolution is mostly driven by treatment-induced selection of sub-clones, underlining the need for novel, non-genotoxic treatment regimens.
克隆进化涉及慢性淋巴细胞白血病 (CLL) 的进展。为了将进化模式与不同的疾病过程联系起来,我们对 CLL 患者进行了一项长期的纵向突变分析研究。跟踪体细胞突变及其等位基因频率随时间的变化,并评估潜在的癌细胞分数,揭示了高度不同的进化模式。令人惊讶的是,在长期稳定的疾病和治疗后长时间临床缓解后的复发中,克隆转移较小。相比之下,在难治性疾病中,主要的克隆转移发生,尽管对白血病细胞计数的影响很小。由于这种难治性病例中的显著模式与已知的 CLL 驱动基因的强烈贡献无关,因此进化主要是由治疗诱导的亚克隆选择驱动的,这凸显了对新型非遗传毒性治疗方案的需求。